Pomerantz Law Firm Files Class Action Against Atara Biotherapeutics

Lawsuit alleges company misled investors about drug candidate's regulatory prospects

Mar. 31, 2026 at 8:21pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a shattered glass vial and a cracked tablet on a clean, monochromatic background, conceptually representing the regulatory and manufacturing issues that plagued Atara's drug candidate.Shattered symbols of a biotech company's regulatory troublesLos Angeles Today

Pomerantz LLP has filed a class action lawsuit against Atara Biotherapeutics, Inc. and certain officers, alleging the company made materially false and misleading statements about its lead drug candidate tabelecleucel during a class period from May 2024 to January 2026. The lawsuit claims Atara overstated tabelecleucel's regulatory prospects and failed to disclose manufacturing issues and study design flaws that made FDA approval unlikely.

Why it matters

This lawsuit highlights the risks biotech companies face when making overly optimistic claims about their drug pipelines. Investors rely on accurate information to make informed decisions, and allegations of securities fraud can severely damage a company's reputation and stock price.

The details

The class action, filed in the U.S. District Court for the Central District of California, alleges Atara misled investors about the prospects for its lead product candidate tabelecleucel, a T-cell immunotherapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The complaint claims Atara failed to disclose manufacturing issues and design flaws in the ALLELE study that supported its Biologics License Application, making FDA approval unlikely. After the FDA issued complete response letters citing these problems, Atara's stock price plummeted.

  • Atara submitted a Biologics License Application for tabelecleucel in May 2024.
  • In January 2025, the FDA issued a Complete Response Letter regarding the tabelecleucel BLA.
  • Also in January 2025, the FDA placed a clinical hold on Atara's active Investigational New Drug applications.
  • In July 2025, Atara resubmitted the tabelecleucel BLA to the FDA.
  • In January 2026, the FDA issued another Complete Response Letter, stating the ALLELE trial was no longer adequate to demonstrate effectiveness.

The players

Pomerantz LLP

A law firm that specializes in corporate, securities, and antitrust class action litigation, and has recovered billions in damages for class members.

Atara Biotherapeutics, Inc.

A biopharmaceutical company developing therapies for solid tumors, hematologic cancers, and autoimmune diseases.

Got photos? Submit your photos here. ›

What they’re saying

“The class action, filed in the United States District Court for the Central District of California, and docketed under 26-cv-03083, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Atara securities during the Class Period, seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.”

— Danielle Peyton, Attorney, Pomerantz LLP

What’s next

Investors who purchased Atara securities during the class period have until May 22, 2026 to request to be appointed as lead plaintiff in the lawsuit.

The takeaway

This case highlights the importance of biotech companies providing accurate and transparent information to investors about the regulatory status and development challenges of their drug candidates. Overstating a product's prospects can lead to significant legal and financial consequences.